Advanced CPhT study materials
Advanced CPhT study resources

Normal Saline Backorder: Choosing a Compliant Path

Advanced CPhT · Put your knowledge to work in context.

All case studies

Normal Saline Backorder: Choosing a Compliant Path

You are the lead technician at a 180-bed community hospital. Your wholesaler just notified you that 100 mL 0.9% sodium chloride IV bags are on 100% allocation through the end of the quarter. At current use of roughly 240 bags per day, you have about six days of supply. Options on the table: (a) switch adult med-surg patients to 250 mL bags and adjust the smart-pump library, (b) purchase from a registered 503B outsourcing facility, (c) compound 100 mL bags in-house from sterile water and 23.4% sodium chloride concentrate in your USP <797> cleanroom, (d) obtain imported product. Nursing says, "Just switch to 250 mL, it's the same drug." Your pharmacy director is on vacation and has asked you to draft the contingency plan by tomorrow morning.

1. Rank the four options and justify your ranking using both regulatory and clinical reasoning. Specifically, what makes in-house compounding permissible or impermissible here?

Read the worked answer

Ranking: 503B first for volume, 250 mL switch as the bridge, in-house compounding only as a narrow gap-filler, importation last and not by you.

Reasoning, not rule-recall:

  • Option (b), 503B: An outsourcing facility can supply large volume with a documented BUD and sterility assurance, and it is the least disruptive to nursing workflow. Constraints are real: minimum order quantities, lead time (often 1–3 weeks), cost premium, and you must verify the facility is registered and the product is on its FDA-registered list. If lead time exceeds your six days of supply, 503B alone cannot be the answer.
  • Option (a), 250 mL switch: Clinically acceptable for most adults but not for fluid-restricted patients (heart failure, renal impairment, some post-op), neonates, or small pediatrics. 250 mL delivers 2.5x the free water and sodium. This is a prescriber order change, not a substitution - it needs an order-set build, an EHR flag for fluid-restricted patients, pump-library validation, and label differentiation so a nurse does not program a 250 mL bag against a 100 mL order.
  • Option (c), in-house compounding: The key test is whether the CSP is essentially a copy of a commercially marketed product. During a documented national shortage, 503A compounding of that product is generally permitted, but you must have the shortage documentation on file, validated sterilization/aseptic SOPs, and assign a BUD per your USP <797> category for the actual conditions (component sterilization, storage, container). If you cannot demonstrate the shortage documentation and validated process, this option is not defensible.
  • Option (d), importation: Only under FDA's temporary importation authority, with specified NDCs, labeling, and often a specific distributor. A hospital technician does not initiate this unilaterally.

Bottom line: 503B for the bulk, 250 mL for the med-surg bridge with the safety build, in-house compounding for the fluid-restricted/pediatric gap if the volume is small and the process is validated.

2. What must be in place before the 250 mL switch goes live, and what will you measure to know it worked?

Read the worked answer

Pre-go-live build (each item prevents a specific failure mode):

  1. Prescriber-approved conversion protocol - a standing order or protocol signed by the P&T committee / medical staff, so nursing is not substituting on their own authority. Without this, you have created an unapproved order change.
  2. EHR guardrails - an exclusion for fluid-restricted and pediatric/neonatal patients, weight-based max-volume alerts, and an order-set default that reflects reality.
  3. Pump library update plus validation - new drug entry for 250 mL with the correct volume, and a documented test on a demo pump. An unvalidated library entry is how rate errors happen.
  4. Label and storage differentiation - auxiliary "250 mL - volume change" labels and physically separated storage so a 250 mL bag is not pulled against a 100 mL order.
  5. Nursing and prescriber communication with a named contact and an escalation path.

Metrics:

  • Process: bags dispensed per day by type, number of order conversions, override/alert fatigue on the fluid-restricted flag, returns/waste.
  • Outcome: volume-related adverse events, hypernatremia or fluid-overload labs in flagged patients, unexpected weight changes, pump-programming events.
  • Balancing measure: therapy delays from stockouts and turnaround time on the 503B orders.

Report weekly to P&T until the shortage resolves; a single week of "no events" is not evidence of safety with only 240 bags/day.

3. Draft the core of the message to nursing and prescribers. What content must it contain so the change does not itself cause a new error?

Read the worked answer

A shortage memo that says only "100 mL bags are out, use 250 mL" reliably generates a new class of error. The message needs five elements:

  1. Why - one sentence of factual context (allocation percentage, estimated duration). Staff tolerate change far better when the reason is real.
  2. What is different and for whom - explicitly name the excluded populations (fluid-restricted, neonates, pediatrics, patients on strict intake/output) and say what those staff should do instead (call pharmacy for the compounded 100 mL supply).
  3. What to do differently in the workflow - where to find the product, how to program the pump, that the order must be rewritten rather than verbally substituted, and that the label will look different.
  4. Where to escalate - a named person and a phone number, plus what to do if the supply runs out mid-shift (the contingency, not a shrug).
  5. What to watch for and report - a short list of the specific things you want reported (fluid overload signs, pump discrepancies, near-misses), so the change is being monitored by the people closest to it.

Send it once, then a short daily huddle update for the first week. A single blast email with no follow-up is the most common way a shortage plan fails.